Out Fox The $treet

Update - Mar. 18, 2025 Tempus AI continues to slow to the lows below $50 now. The stock is tasty once the shake out is over.  Originally posted on Feb. 25 Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organic growth with Diagnostics revenue expanding due to higher test ASPs. Concerns over AI replacement have pressured the stock, yet TEM's proprietary data and hospital network provide defensible moats. At 6.5x 2026 sales and strong contract retention, TEM stock appears undervalued; I am ultra Bullish and see current weakness as a buying opportunity. Tempus AI, Inc. ( TEM ) has seen the stock continue to slide over the last few months, leaving Tempus down 50% from the highs. The AI precision medicine company has seen the stock slip back to support in  the $50 to $55 range despite ongoing strong results, including a solid Q4 earnings...

Update - March 12, 2026 Rubrik reports FQ4  after the close. The current consensus is only 23% growth for FY27, so a guide up is likely. -Rubrik ( RBRK ) is scheduled to announce FQ4 earnings results on Thursday, March 12th, after market close. -The consensus EPS Estimate is -$0.11 (+38.9% Y/Y) and the consensus Revenue Estimate is $342.37M (+32.7% Y/Y) -------- FQ4 Non-GAAP EPS of $0.04  beats by $0.15 . Revenue of $377.68M (+46.3% Y/Y)   beats by $35.31M . FQ1 r evenue guidance of $365 million to $367 million vs consensus of $350.56M. FY27 revenue guidance of  $1,597 million to $1,607 million vs consensus of $1.58B. Original article posted on Feb. 12 Rubrik has declined over 50%, creating a compelling value entry for this AI-driven cybersecurity leader. RBRK's subscription ARR surged 34% in FQ3 2026 to $1.35 billion, with guidance for $1.44 billion by FY 2026 year-end. The stock trades at just 7x FY 2027 revenue and closer to 6x ARR, positioning RBRK as a top value...

Updated - March 11, 2026 Nebius has bounced back above $105 on the  NVDA  investment deal and strong earnings from Oracle. The neocloud stocks finally look ready for a breakout rally.  -Nvidia ( NVDA ) will invest $2B in Nebius ( NBIS ), and the two companies have formed a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market. -Shares of Nebius jumped about 10% premarket on Wednesday, while Nvidia was largely flat. -The Dutch AI infrastructure provider said the partnership will help it deploy more than 5 gigawatts of Nvidia systems by the end of 2030. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » Original article posted on Feb. 15 Nebius Group N.V. reported a strong ending ARR total, but the market is stuck focused on short-term revenue hiccups. NBIS is positioned as an AI cloud leader, suggesting strong long-term growt...

Updated - March 7, 2026 HIMS  closed up 40% in AHs on a surprise twist with  NVO  agreeing to a partnership.  Hims was a $30 last month and the stock trades at only 1x 2026 sales estimates of $2.7 billion.  -Novo Nordisk ( NVO ) is planning to sell its obesity drugs on the telehealth platform run by Hims & Hers Health ( HIMS ) as part of a partnership between the two firms, Bloomberg reported, citing a person familiar with the matter. -The companies are set to announce the deal as early as Monday, according to the person who sought anonymity, as the information is not yet public. -A spokesperson for the Danish drugmaker told Bloomberg, “We are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases. These talks happen on an ongoing basis.” HIMS was not available for comments outside regular business hours. Looking for a portfolio of ideas like this one? Members of Out Fox Th...

  Originally posted on Feb. 11 Red Cat Holdings enters Q4 earnings near highs, with anticipation building for its February 27 Innovation Day and updated long-term targets. The drone company offered preliminary Q4 revenue numbers of $24–$26.5 million, a dramatic increase from prior quarters. RCAT's valuation is compelling versus peers, trading at just 10x 2026 sales targets, with a strong $213 million cash balance and less dilution risk than Ondas. Upcoming Innovation Day could provide clarity on USV division growth and expanded order pipeline, offering potential upside to current conservative revenue targets. Red Cat Holdings, Inc. ( RCAT ) enters Q4 earnings with the stock trading back towards the highs. The company has an Innovation Day presentation each month to finally provide the market with some insights into 2026  targets and long-term goals. My  investment thesis  remains Bullish on the stock, though Red Cat isn't as cheap now as the multiple opportunities t...

  SentinelOne enters FQ4 earnings with shares trading at a yearly low due in part to AI-driven sector fears. The cybersecurity company has made a strong transition to AI-native products via internal development and recent AI-related acquisitions. The stock is cheap below 4x forward sales, while the FY27 guidance is expected to top 20% growth. SentinelOne, Inc.  ( S ) heads into FQ4 earnings with the stock oddly not trading down much over the last week due to the AI replacement fears. The cybersecurity stock was already trading substantially lower over the last 6 months due  to fears unexplained by the financial results. My  investment thesis  is ultra Bullish on SentinelOne, with signs some AI-related acquisitions are paying off. Read the full article on Seeking Alpha.  Disclosure: Long S. Please review the disclaimer page for more details.